QMS Medical Allied Services FY26: Revenue Climbs to ₹173 Cr, Profit Slips to ₹10 Cr — and the Ticker Just Changed Boards
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. At a Glance
QMS Medical Allied Services closed FY26 with a split-screen result. Revenue rose to ₹172.9 crore from ₹155.8 crore, an 11% climb. Net profit went the other way, sliding to ₹10.1 crore from ₹12.1 crore — a 16% fall. So the top line grew and the bottom line shrank in the same year, which is the kind of tension a reference entry exists to record.
Two structural facts frame the year. First, the company migrated from NSE Emerge to the NSE Mainboard on 18 June 2026, its 1.93 crore shares moving to the bigger stage after four years on the SME platform. Second, the fourth quarter carried the profit damage: Q4FY26 net profit landed at ₹1.72 crore against ₹3.34 crore a year earlier, a 48.5% drop, on near-flat quarterly sales.
The attention signal is a business that grew revenue for the year while spending its way through a soft quarter. The worry signal sits in working capital — receivables and the cash conversion cycle both stretched. A company can invest ahead of revenue and call it strategy; the accounts simply record the timing gap. The rest of this entry lays out the numbers behind that gap.
2. Introduction
QMS was incorporated in its current corporate form in 2017, though the operating lineage runs back to 1994 as a pharma-marketing and medical-device distribution business. It distributes third-party brands — 3M, Heine, Rossmax among them — alongside its own Q-Devices label launched in FY21, covering glucometers, oximeters, BP monitors and similar hardware. Over 900 SKUs move to 130-plus institutional clients, including a long list of pharmaceutical companies.
The more recent chapter is services. The company built out patient support programs (PSPs), B2B screening camps and medical-education content, and folded in Saarathi Healthcare, whose stake management raised to 76% during the year. By FY26 the split was 69% products, 31% services, with management stating the intent to tilt the mix toward the higher-margin service side over time.
Two events dominated the year’s filings: the mainboard migration in June 2026, and a rights issue that brought in roughly ₹10.4 crore, lifting the share count from 1.785 crore to 1.934 crore. The board also recommended a dividend of ₹0.50 per share for FY26 — the first on record here. Everything else this entry discusses hangs off those moves and the numbers around them.
3. Business Model: WTF Do They Even Do?
Strip away the healthcare-ecosystem language and QMS runs two shops under one roof.
Shop one is distribution. QMS buys or sources medical devices — the third-party global brands plus its own Q-Devices line — and sells them to pharma companies, hospitals, clinics, and through its QMSMEDS e-commerce portal and the government eGrameen channel. It’s a margin-taking middleman with a house brand bolted on for better economics. Management pegs product-side EBITDA margins in the roughly 10–12% band. Honest work, thin spreads, and 900 SKUs to babysit.
Shop two is where the interesting money hides. The services arm sells three things: pharma-sponsored screening camps (32,380 of them conducted in FY26), patient support programs run under fixed-cost-plus contracts, and small high-margin medical-education content. The camps run on a pay-per-camp model where the pharma company foots the bill — not the patient, not the doctor. Management stated services-side EBITDA margins sit around 25%, more than double the product side. The strategic pitch writes itself: sell more of shop two, less of shop one.
The catch is that shop two costs money up front. PSP contracts get signed months before billing starts, and the staff to run them get hired first. So the services pivot that improves the margin mix on paper also front-loads the expense line — which is precisely the story FY26’s profit told.
A model where your best-margin business bills you before it pays you is a working-capital business wearing a growth-stock costume. Does the mix shift toward 25% services margins fix a 6% net margin, or just move the strain from the P&L to the balance sheet?
